| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 | ||
| FORM 8-K CURRENT REPORT | ||
| Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | ||
| Date of Report (Date of earliest event reported): May 19, 2011 | ||
| ENZON PHARMACEUTICALS, INC. | ||
| (Exact name of registrant as specified in its charter) | ||
| Delaware |
0-12957 |
22-2372868 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 20 Kingsbridge Road, Piscataway, New Jersey | 08854 | |
| (Address of principal executive offices) | (Zip Code) |
| (732) 980-4500 | ||
| (Registrant’s telephone number, including area code) | ||
|
Not Applicable Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
Item 8.01 Other Events.
On May 19, 2011, Enzon Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
|
Exhibit No.
|
Description
| |
| 99.1 | Press Release of Enzon Pharmaceuticals, Inc. dated May 19, 2011 | |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ENZON PHARMACEUTICALS, INC. | ||||||
| (Registrant) | ||||||
| Date: | May 19, 2011 | By: /s/ Andrew Rackear | ||||
| Name: | Andrew Rackear | |||||
| Title: | Vice President and General Counsel | |||||
EXHIBIT INDEX
|
Exhibit No.
|
Description
| |
| 99.1 | Press Release of Enzon Pharmaceuticals, Inc. dated May 19, 2011 | |
| Investor Contact: | Andrea Rabney | ||
| Argot Partners | |||
| 212.600.1902 | |||
| andrea@argotpartners.com | |||
| Media Contact: | Meghan Feeks | ||
| Argot Partners | |||
| 212.600.1902 | |||
| meghan@argotpartners.com | |||
Enzon Announces Discontinuation of PEG-SN38 Program in
Metastatic Colorectal Carcinoma in Light of Evolving Standards of Care
-- PEG-SN38 Clinical Programs Continue in Metastatic Breast Cancer, Other Solid Tumors--
PISCATAWAY, N.J. May 19, 2011---Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study. Enzon continues to enroll studies for the Company’s other PEG-SN38 programs, which include a soon-to-be fully enrolled Phase II study in metastatic breast cancer, a Phase I study in pediatric cancer, and a Phase I study in combination with Avastin® (bevacizumab injection) in solid tumors.
“While we may evaluate PEG-SN38 in earlier lines of colorectal cancer treatment in future clinical trials, at this time, resources associated with such trials are better directed toward areas of study with nearer-term commercial potential,” said Richard Mulligan, Ph.D., Vice-Chairman of Enzon’s Board of Directors. “We remain highly encouraged by the promising activity and safety of PEG-SN38 in a number of cancers, including metastatic breast cancer, and look forward to the rapid execution of studies in areas in which the full benefit of irinotecan cannot be realized due to toxicity.”
About Enzon
Enzon Pharmaceuticals, Inc. is a biotechnology company dedicated to the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Enzon’s drug-development programs utilize two platforms – Customized PEGylation Linker Technology (Customized Linker Technology®) and third-generation mRNA-targeting agents utilizing the Locked Nucleic Acid (LNA) technology. Enzon currently has four compounds in clinical development and multiple novel LNA targets in preclinical research. Enzon receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its Customized Linker Technology. Further information about Enzon and this press release can be found on the Company’s website at www.enzon.com.
Forward Looking Statements
There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such
as the words "believes," "expects," "may," "will," "should,” "potential,"
"anticipates," "plans," or "intends" and similar expressions. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially
different from the future results, events or developments indicated in such forward-looking statements. Such factors include but
are not limited to the timing, success and cost of clinical studies for Enzon’s product candidates, the ability to obtain
regulatory approval of Enzon’s product candidates, Enzon’s ability to obtain the funding necessary to develop its product
candidates, market acceptance of and demand for Enzon’s product candidates, and the impact of competitiive products, pricing
and technology. A more detailed discussion of these and other factors that could affect results is contained in Enzon's filings
with the U.S. Securities and Exchange Commission, including Enzon's most recent Annual Report on Form 10-K for the year ended December
31, 2010 . These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking
statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information
in this press release is as of the date of this press release and Enzon does not intend to update this information.